Immunoglobulin Replacement Therapy is critical and cost-effective in increasing life expectancy and quality of life in patients suffering from Common Variable Immunodeficiency Disorders (CVID): A health-economic assessment
Fig 4
The difference in health outcome between the three simulated cohorts.
Intervention group: 1,000 simulated patients treated with a mean literature-based-dose of IgGRT (≥450 mg/kg/4 weeks); delayed intervention group (4 years): The first 48-months cycles of the intervention group were replaced by the values of the control group; control group: 1,000 simulated patients treated with zero-to-low-dose IgGRT regimens (0 to ≤100 mg/kg/4 weeks). Y-axis: Years gained. LYs, Life-years; QALYs, Quality-adjusted Life-years.